1. Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model
   Ji Hoon Phi et al, 2017, Oncotarget CrossRef
2. Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells
   Zhang-Xu He et al, 2021, European Journal of Medicinal Chemistry CrossRef
3. Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
   Bi Lian et al, 2023, Frontiers in Immunology CrossRef
4. Novel indole hydrazide derivatives: Synthesis and their antiproliferative activities through inducing apoptosis and DNA damage
   Zühal Kilic‐Kurt et al, 2020, Archiv der Pharmazie CrossRef
5. Acetylation of conserved DVL-1 lysines regulates its nuclear translocation and binding to gene promoters in triple-negative breast cancer
   Monica Sharma et al, 2019, Scientific Reports CrossRef
6. β-Cyclodextrin-poly (β-Amino Ester) Nanoparticles Are a Generalizable Strategy for High Loading and Sustained Release of HDAC Inhibitors
   Sauradip Chaudhuri et al, 2021, ACS Applied Materials & Interfaces CrossRef
7. Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics
   Yuan Seng Wu et al, 2019, Current Cancer Drug Targets CrossRef
8. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators
   Lyndsay V. Rhodes et al, 2014, Breast Cancer Research and Treatment CrossRef
9. Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
   Jiawei Li et al, 2023, Biology CrossRef
10. Exploring the Molecular Mechanism of Cinnamic Acid-Mediated Cytotoxicity in Triple Negative MDA-MB-231 Breast Cancer Cells
    Ambika Pal et al, 2021, Anti-Cancer Agents in Medicinal Chemistry CrossRef
11. Novel thiosemicarbazone derivatives containing indole fragment as potent and selective anticancer agent
    Zhangxu He et al, 2019, European Journal of Medicinal Chemistry CrossRef
12. Targeting protein quality control pathways in breast cancer
    Sara Sannino et al, 2017, BMC Biology CrossRef
13. A Review on Epigenetic Effects of Environmental Factors Causing and Inhibiting Cancer
    Fatemeh Khaledi et al, 2022, Current Molecular Medicine CrossRef
14. Singlet Anticancer Therapy Through Epi-Weapons Histone Deacetylase Inhibitors and Its Shortcomings
    Shabir Ahmad Ganai, 2020, Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy CrossRef
15. Small molecule HDAC inhibitors: Promising agents for breast cancer treatment
    Meiling Huang et al, 2019, Bioorganic Chemistry CrossRef
16. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
    Tao Yan-Fang et al, 2015, PLOS ONE CrossRef
17. Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer
    Sumin Oh et al, 2017, Translational Research in Breast Cancer CrossRef
18. Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression
    Jing Yang et al, 2017, Scientific Reports CrossRef
19. Structurally Diverse Histone Deacetylase Photoreactive Probes: Design, Synthesis, and Photolabeling Studies in Live Cells and Tissue
    Shaimaa M. Aboukhatwa et al, 2019, ChemMedChem CrossRef
20. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
    M. Janaki Ramaiah et al, 2021, Life Sciences CrossRef
21. Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening
    Xinxin Rao et al, 2024, Pharmaceuticals CrossRef
22. Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs
    Thomas W. Hanigan et al, 2017, PLOS ONE CrossRef